SCHEMBL20600296

SCHEMBL20600296

CC(C)(C)c1cc(NC(=O)c2csc(Nc3cccc(Cl)c3)n2)no1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.61
MAPT P10636 7/20 0.48
GAA P10253 2/20 0.48
FLT3 P36888 3/20 0.48
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
RAPGEF3 O95398 1/20 0.46
ALB P02768 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
ATM Q13315 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600302 0.91 CCR4 (0.52) KDM1AMAPTGAAFLT3KMT2A
SCHEMBL20621341 0.91 KDM1A (0.57) KDM1AMAPTGAAKMT2AMEN1
SCHEMBL20600402 0.90 KDM1A (0.58) KDM1AMAPTFLT3RAB9ANPC1
SCHEMBL20600312 0.90 RAB9A (0.57) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600109 0.87 SMN1; SMN2 (0.49) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600124 0.87 FLT3 (0.45) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600306 0.86 SMN1; SMN2 (0.62) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600165 0.86 SMN1; SMN2 (0.51) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600418 0.85 FLT3 (0.48) KDM1AMAPTFLT3KMT2AMEN1
SCHEMBL20600407 0.84 MAPK14 (0.58) KDM1AMAPTFLT3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3645531-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS Bayer Aktiengesellschaft (DE) 2020-05-06 EP claimed
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-04-23 US claimed
WO-2019002074-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2019-01-03 WO claimed
EP-3645531-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS Bayer Aktiengesellschaft (DE) 2020-05-06 EP disclosed
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-04-23 US disclosed
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-04-23 US disclosed
WO-2019002074-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 KDM1A 162/4885MAPT 3674/4885GAA 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.